Is AT673 legal in Australia?

A GIP receptor antagonist being added to semaglutide in a phase 2 trial of 150 people. It is the exact mirror of NNC0480-0389, which adds a GIP agonist to the same drug.

If you want one fact that captures how unsettled incretin pharmacology is, it is this pair. Two companies are in phase 2 adding opposite interventions at the same receptor to the same background drug, for the same indication, at the same time.

Mechanism: An antagonist at the GIP receptor, intended to block rather than activate the receptor tirzepatide agonises, given alongside a GLP-1 receptor agonist. The mechanistic case comes from GIP receptor knockout mice being protected against diet-induced obesity, and from the observation that a naturally occurring truncated GIP fragment blocks its own receptor in humans.

Regulatory history: Investigational. Not approved anywhere. Phase 2 recruiting.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for AT673 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.